Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

Inclusion Criteria: All Participants: * Age: 18 to 75 years of age (inclusive). * Weight greater than (\>) 45 kilograms (kg) and body mass index (BMI) 18.5 - 40 kg per square meter (kg/m\^2) (inclusive). * Male and female- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies; not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow contraceptive guidance during the treatment period and until at least 4 weeks after the last dose of study treatment. * Participant capable of giving signed informed consent. Participants with Moderate Hepatic Impairment (Cohort 1): * Moderate hepatic impairment (of any etiology) and clinically stable for at least 1 month prior to screening. * Child-Pugh score of 7-9. * Previous confirmation of liver cirrhosis confirmed by either- Liver biopsy, Imaging technique, or Noninvasive liver assessment consistent with cirrhosis. * Hepatic impairment needs to be chronic (\>6 months), stable. Matched Healthy Control Participants (Cohort 2): * Participants will be matched by age plus or minus (±)10 years to a corresponding participant in the hepatic impairment group. Age should remain between 18 and 75 years of age (inclusive). * Participants will be matched by total body weight ±15 percentage (%) to a corresponding participant in the hepatic impairment group. * Participants will be matched by gender and race to a corresponding participant in the hepatic impairment group. * Healthy participant as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. Exclusion Criteria: All Participants: * Participants are excluded from the study if any of the following medical conditions apply: * History of cholecystectomy, current symptomatic cholelithiasis or inflammatory gallbladder disease. * Significant history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. * Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history review), clinical laboratory tests, or 12-lead ECG. * Current clinically significant diarrhea. * History of gastrointestinal surgery with ileal resection or ileal bypass at any time. * Any malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin disease for 3 years. * Participants with unstable cardiac function or participants with uncontrolled hypertension. * Any current medical or psychiatric condition, clinical or laboratory abnormality, or examination finding which may affect study compliance or investigational procedures or possible consequences of the study. * Administration of any other Ileal bile acid transport (IBAT) inhibitor (including linerixibat) in the 3 months prior to screening. * For healthy participants, past or intended use of over the counter or prescription medication, including vitamins and dietary or herbal supplements) within 7 days prior to the first dose of study medication. * Current enrolment in a clinical trial or recent participation in a clinical trial and has received an investigational product within the following time-period prior to study drug administration in the current study: 30 days. * Positive pregnancy test at screening or at Day -1 in women of childbearing potential. * Positive human immunodeficiency virus (HIV) antibody test. * Healthy control participant has corrected interval using the Fridericia's QT correction formula (QTcF) \>450 millisecond (msec); or participant with hepatic impairment has a baseline QTcF \>480 msec on ECG. * Regular use of known drugs of abuse or history of drug abuse or dependence within 6 months of the study. * Moderate (or greater) alcohol consumption defined as one standard drink per day for women and two drinks per day for men. * History of regular use of tobacco or nicotine-containing products. * Positive drug/alcohol screen at Screening or at Day -1. * Where participation in the study would result in donation of blood or blood products more than 500 milliliter (mL) within a 56-day period. * Unwillingness or inability to follow the procedures outlined in the protocol. * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that contraindicates participation in the study. Participants with Hepatic Impairment (Cohort 1): * History of gastric or oesophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated medically or endoscopically. * Grade 3 ascites (large ascites with marked abdominal distension) refractory to medical therapy. * Refractory hepatic encephalopathy as judged by the investigator. * Child-Pugh score of 10 or higher or Child-Pugh score of 6 or lower. * Hepatopulmonary or hepatorenal syndrome and history of liver transplantation. * Evidence of active infection, including spontaneous bacterial peritonitis. * Confirmed hepatocellular carcinoma (HCC) or biliary cancer. * Alanine amino transferase (ALT) value \>3 x upper limit of normal (ULN). * Platelet count less than (\<) 50,000/microliter (μl). Matched Healthy control participants (Cohort 2): * Current or chronic history of liver disease or known hepatic or biliary abnormalities and/or confirmed hepatocellular carcinoma or biliary cancer. * Screening ALT or aspartate aminotransferase (AST) above the upper limit of normal (ULN). * Elevated bilirubin above the ULN unless this is due to underlying Gilbert's syndrome. * Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention. * Positive hepatitis C antibody ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.